# **Complete Summary**

#### **TITLE**

Sepsis: percent of patients with severe sepsis/septic shock who received a recommended broad-spectrum antibiotic within 24 hours following severe sepsis/septic shock identification.

## SOURCE(S)

VHA, Inc. Transformation of the intensive care unit: sepsis data collection toolkit. Irving (TX): VHA, Inc.; 2007 Jan 1. 29 p.

## **Measure Domain**

#### **PRIMARY MEASURE DOMAIN**

**Process** 

The validity of measures depends on how they are built. By examining the key building blocks of a measure, you can assess its validity for your purpose. For more information, visit the <u>Measure Validity</u> page.

## **SECONDARY MEASURE DOMAIN**

Does not apply to this measure

## **Brief Abstract**

## **DESCRIPTION**

This measure is used to assess the percent of patients with severe sepsis/septic shock who received a recommended broad-spectrum antibiotic within 24 hours following severe sepsis/septic shock identification.

#### **RATIONALE**

Studies show that annually there are between 500,000 to one million cases of sepsis and severe sepsis in American hospitals. The annual mortality rate for these cases is between 15 and 30 percent or as many as 200,000 deaths. Many more patients suffer from permanent organ damage. The cost to society in dollars spent and lives lost prematurely is enormous. While there are many useful clinical interventions, research shows that they are applied inconsistently, if at all.

There is emerging evidence that the sickest patients should be treated with broadspectrum antibiotics as soon as possible. This approach contrasts with treatment for less sick patients where, in general, we start with a narrow-spectrum antibiotic and broaden antibiotics if the patient does not respond.

With critically ill patients (those with severe sepsis or septic shock), clinicians cannot afford to under treat. Evidence suggests that the initial use of inadequate antibiotics nearly doubles the patients' mortality. As a result, the approach to antibiotic management in patients with severe sepsis or septic shock should be to start broad as soon as possible until culture results are available and the regimen can be narrowed.

Just what constitutes adequate broad-spectrum antibiotic coverage is an ongoing controversy. Because pseudomonas is a common pathogen, the initial antibiotic therapy should include a medication against pseudomonas. Increasingly, methicillin-resistant staph aureus (MRSA) is a cause of infection and one of the most common reasons for inadequate antibiotic therapy. In addition, a recent study suggests that 12 percent of MRSA infections were community-acquired and these patients lacked established risk factors. Because our ability to predict who is at risk for pseudomonas and MRSA is imprecise and because a patient's mortality nearly doubles if infections with these organisms go untreated with the initial antibiotics, we recommend that unless the clinician is confident that the probability of pseudomonas or MRSA is zero, an antibiotic to treat pseudomonas and MRSA should be included in the initial antibiotic therapy for critically ill patients.

The potential downside of this strategy is enhanced antibiotic resistance. Though the data is limited, most experts believe that four days of antibiotics is unlikely to cause resistance. Resistance ensues when the drugs are continued for long periods of time. Among critically ill patients, the risk-benefit ratio thus strongly favors starting broad-spectrum antibiotics that includes anti-pseudomonal and MRSA drugs. These antibiotics should be discontinued if not needed when culture results are available.

#### PRIMARY CLINICAL COMPONENT

Severe sepsis; septic shock; broad spectrum antibiotic administration

#### DENOMINATOR DESCRIPTION

Total number of patients, 16 years of age and older, with a diagnosis of severe sepsis/septic shock (see the related "Denominator Inclusions/Exclusions" field in the Complete Summary)

### **NUMERATOR DESCRIPTION**

Number of patients who received a recommended broad-spectrum antibiotic within 24 hours prior to and 24 hours following severe sepsis/septic shock identification (see the related "Numerator Inclusions/Exclusions" field in the Complete Summary)

# **Evidence Supporting the Measure**

# **EVIDENCE SUPPORTING THE CRITERION OF QUALITY**

 One or more research studies published in a National Library of Medicine (NLM) indexed, peer-reviewed journal

# **Evidence Supporting Need for the Measure**

#### **NEED FOR THE MEASURE**

Unspecified

# **State of Use of the Measure**

#### **STATE OF USE**

Current routine use

#### **CURRENT USE**

Collaborative inter-organizational quality improvement Internal quality improvement Quality of care research

# **Application of Measure in its Current Use**

#### **CARE SETTING**

Hospitals

## PROFESSIONALS RESPONSIBLE FOR HEALTH CARE

Advanced Practice Nurses Nurses Physicians

## **LOWEST LEVEL OF HEALTH CARE DELIVERY ADDRESSED**

Single Health Care Delivery Organizations

## **TARGET POPULATION AGE**

Age greater than or equal to 16 years

## **TARGET POPULATION GENDER**

Either male or female

#### STRATIFICATION BY VULNERABLE POPULATIONS

Unspecified

# **Characteristics of the Primary Clinical Component**

## **INCIDENCE/PREVALENCE**

See the "Rationale" field.

#### **ASSOCIATION WITH VULNERABLE POPULATIONS**

Unspecified

## **BURDEN OF ILLNESS**

See the "Rationale" field.

#### **UTILIZATION**

Unspecified

#### **COSTS**

A study confirmed that patients with severe sepsis consume significant resources. The average hospital length of stay was 20 days at an average cost of \$22,100. National cost estimates for the care of severe sepsis based on this study is \$16.7 billion dollars, with the care of patients older than 65 costing \$8.7 billion (52.3 percent), and care of those older than 75 costs \$5.1 billion dollars (30.8 percent). The costs for caring for patients with sepsis are projected to rise approximately 1.5 percent per year due to the aging U.S. population.

#### **EVIDENCE FOR COSTS**

VHA, Inc. Improving sepsis care in the intensive care unit: an evidence-based approach. Irving (TX): VHA, Inc.; 2004. 60 p.

**Institute of Medicine National Healthcare Quality Report Categories** 

#### **IOM CARE NEED**

Getting Better

#### **IOM DOMAIN**

Effectiveness

#### **CASE FINDING**

Users of care only

#### **DESCRIPTION OF CASE FINDING**

Patients, 16 years of age and older, with a diagnosis of severe sepsis/septic shock

#### **DENOMINATOR SAMPLING FRAME**

Patients associated with provider

## **DENOMINATOR INCLUSIONS/EXCLUSIONS**

#### **Inclusions**

Total number of patients, 16 years of age and older, with a diagnosis of severe sepsis/septic shock

#### **Exclusions**

Any one of the following:

- Patients less than 16 years of age
- If the organism responsible for severe sepsis/septic shock has been identified AND "None of the above" was selected from recommended broad-spectrum antibiotic list
- Not Applicable because:
  - Patient had severe allergies to ALL the recommended broad-spectrum antibiotics
  - Had contraindications/reasons for not receiving ALL recommended antibiotics
  - Care was withdrawn or patient expired within 24 hours following severe sepsis/septic shock identification
- "None of the above based on national guidelines" (e.g., necrotizing fasciitis or bacterial meningitis) was selected from recommended broad-spectrum antibiotic list
- Date or Time of severe sepsis/septic shock identification unknown
- Cases with a time elapsed EARLIER THAN -24 hours or GREATER THAN +72 hours. Time elapsed is the difference between severe sepsis/septic shock identification and the administration of a recommended broad-spectrum antibiotic.

**Note**: Refer to the original measure documentation for definitions and additional details.

#### RELATIONSHIP OF DENOMINATOR TO NUMERATOR

All cases in the denominator are equally eligible to appear in the numerator

### **DENOMINATOR (INDEX) EVENT**

#### **DENOMINATOR TIME WINDOW**

Time window brackets index event

## **NUMERATOR INCLUSIONS/EXCLUSIONS**

#### **Inclusions**

Number of patients who received a recommended broad-spectrum antibiotic\* within 24 hours prior to and 24 hours following severe sepsis/septic shock identification

\*Refer to the original measure documentation for broad-spectrum antibiotic recommendations.

#### **Exclusions**

Date or Time of recommended broad-spectrum antibiotic administration unknown.

# MEASURE RESULTS UNDER CONTROL OF HEALTH CARE PROFESSIONALS, ORGANIZATIONS AND/OR POLICYMAKERS

The measure results are somewhat or substantially under the control of the health care professionals, organizations and/or policymakers to whom the measure applies.

## **NUMERATOR TIME WINDOW**

Fixed time period

## **DATA SOURCE**

Medical record

# LEVEL OF DETERMINATION OF QUALITY

Individual Case

## PRE-EXISTING INSTRUMENT USED

Unspecified

# **Computation of the Measure**

## **SCORING**

Rate

## **INTERPRETATION OF SCORE**

Better quality is associated with a higher score

## **ALLOWANCE FOR PATIENT FACTORS**

Unspecified

#### STANDARD OF COMPARISON

Internal time comparison

# **Evaluation of Measure Properties**

#### **EXTENT OF MEASURE TESTING**

Unspecified

# **Identifying Information**

#### **ORIGINAL TITLE**

Recommended antibiotic received within 24 hours following severe sepsis/septic shock identification.

#### **MEASURE COLLECTION**

Transformation of the Intensive Care Unit (TICU) Measures

#### **MEASURE SET NAME**

Sepsis Quality Indicators

#### **DEVELOPER**

VHA, Inc.

# **FUNDING SOURCE(S)**

VHA, Inc.

#### COMPOSITION OF THE GROUP THAT DEVELOPED THE MEASURE

Internal VHA, Inc. clinical subject matter experts along with external clinical subject matter faculty experts from various National and local research medical centers/hospitals

## FINANCIAL DISCLOSURES/OTHER POTENTIAL CONFLICTS OF INTEREST

None; work was not supported by any third party vendors, contractors or forprofit health care companies including suppliers, device makers, or pharmaceutical firms.

# **ADAPTATION**

Measure was not adapted from another source.

#### **RELEASE DATE**

2004 Jan

#### **REVISION DATE**

2007 Jan

#### **MEASURE STATUS**

This is the current release of the measure.

## SOURCE(S)

VHA, Inc. Transformation of the intensive care unit: sepsis data collection toolkit. Irving (TX): VHA, Inc.; 2007 Jan 1. 29 p.

## **MEASURE AVAILABILITY**

The individual measure, "Recommended Antibiotic Received within 24 Hours Following Severe Sepsis/Septic Shock Identification," is published in "Transformation of the Intensive Care Unit: Sepsis Data Collection Toolkit."

For more information, contact VHA, Inc. at: 220 E. Las Colinas Blvd., Irving, TX 75039; Phone: 1-800-842-5146 or 1-972-830-0626; Web site: <a href="https://www.vha.com">www.vha.com</a>.

#### **COMPANION DOCUMENTS**

The following is available:

• VHA, Inc. Improving Sepsis Care in the Intensive Care Unit: An Evidence-Based Approach. Irving (TX): VHA, Inc.; 2004. 60 p.

For more information, contact VHA, Inc. at: 220 E. Las Colinas Blvd., Irving, TX 75039; Phone: 1-800-842-5146 or 1-972-830-0626; Web site: <a href="https://www.vha.com">www.vha.com</a>.

#### **NQMC STATUS**

This NQMC summary was completed by ECRI Institute on September 23, 2008. The information was verified by the measure developer on November 13, 2008.

### **COPYRIGHT STATEMENT**

This NQMC summary is based on the original measure, which is subject to the measure developer's copyright restrictions.

#### Disclaimer

# **NQMC DISCLAIMER**

The National Quality Measures Clearinghouse™ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.

All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.

Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the NQMC Inclusion Criteria which may be found at

http://www.gualitymeasures.ahrg.gov/about/inclusion.aspx.

NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. The inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding measure content are directed to contact the measure developer.

© 2008 National Quality Measures Clearinghouse

Date Modified: 12/8/2008

